GERN Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 0.0%, SMA50 12.29%, SMA200 21.14%). The stock’s 14-day RSI is 51.44 (neutral), while the ATR of 0.15 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -17.91% below its high and over 58.65% above its low. Average 10-day trading volume of 10.83 million shares is below the 3-month average of 14.25 million, indicating normal recent market interest.

Geron Corporation generated EPS of -$0.13 over the past year. Five-year average earnings growth is 14.31%. The latest quarter delivered EPS of -$0.01. The next quarter is forecast at -$0.02. Next year's EPS is expected at -$4.37. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $4.00 to $4.00. The high target offers 181.69% upside. The low target suggests 181.69% downside. The mean target is $4.00. This offers 181.69% upside. Geron Corporation earnings surprise history is a mixed track record. The quarter that ended May 06, 2026, missed forecasts by -66.67%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in February 26, 2025.

Geron Corporation has 638.02 million shares outstanding. The public float is 534.08 million shares, elevated short interest at 12.64% of float. This equals 77.12 million shares. The short ratio is 8.17 days. Institutional investors hold 82.05% of the float. Insiders own 0.09%. GREENWOOD DAVID holds 754.03 thousand shares, LEBKOWSKI JANE has 568.15 thousand shares and Kelsey Stephen Michael has 473.12 thousand shares. Over the past six months, insider transactions show net selling. They sold 9.86 thousand shares across 1 transactions.

Geron Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.03. This means the shares are trading below this model’s fair value.

Geron Corporation (NASDAQ:GERN) closed at $1.42 USD, losing -$0.08 (-5.33%) from the previous close of $1.50. The stock is currently mid-range between its 52-week high and low $1.04 and $2.01. With a market capitalization of about $910.96 million, Geron Corporation is classified as a small-cap and shows lower-than-market volatility (beta ~0.60). Key stats such as the average daily volume over the past year has been around 14.31 million shares, volume is running light vs its 52-week average. Headquartered in Foster City, CA, Geron Corporation operates in the Healthcare sector and the Biotechnology industry. Led by CEO Harout Semerjian, the company employs approximately 258 people and listed since July 31, 1996. Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers.

Geron Corporation trades at a P/E ratio of -13.81, slightly below the S&P 500 average, with a price-to-sales ratio of 4.71 and a price-to-book ratio of 4.21 trading at moderately above to book value. The P/FCF stands at -7.31, also below market averages.

Geron Corporation (NASDAQ:GERN) shares are flat -1.52% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Geron Corporation trading at a premium to the broader market with a P/E of -13.81. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $4.90, suggesting 245.07% upside. Our AI forecast model points to short-term strength (14.79% over two weeks), a medium-term rise (3.52% over three months), and a longer-term gain (353.52% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Geron Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 14.79%, with price expected at $1.63 by July 27, 2026, within a range of $1.56 to $1.69 3-Month Outlook: Projected rise of 3.52%, reaching $1.47 by October 08, 2026, with a range of $1.29 to $1.59. 1-Year Outlook: Projected gain of 353.52%, with price at $6.44 by July 13, 2027, within a range of $0.00 to $8.33.